8th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

CONFERENCE AGENDA

Registration	08:15 - 08:45
Welcome note from MarketsandMarkets Nikita Parab, Associate Director, Conferences, MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairman Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah	08:55 - 09:00
Development of a Kit-Based Assay for Assessing Homologous Recombination Deficiency (HRD) in Ovarian Cancer Amy Wehn, Director, Companion Diagnostics, Merck	09:00 - 09:30
Challenges associated with Clinical Biomarker Validation
End-to-end proteomics services for discovery, validation and deployment of novel biomarkers in drug development and clinical trials Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	09:30 - 10:00
Develop and Validate Cancer Methylation Panel Using Targeted Bisulfite NGS Liying Yan, President, EpigenDx	10:00 - 10:25
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Delivering CDx Excellence: Innovation and Partnerships Deboleena Sarkar, Director Companion Diagnostics Business Development, Qiagen	11:15 - 11:45
BD Biosciences Advancing CDx and clinical trial assay development using flow cytometry Scott Bornheimer , Associate Director, Medical & Scientific Affairs , BD Biosciences	11:45 - 12:15
Current and Future Liquid Biopsy Landscapes in Advanced Prostate cancer: Implications for Clinical Practice Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah	12:15 - 12:45
Turning preclinical findings into clinic-ready biomarker assays to support the phase I/II of BT7480, a Bicycle tumor-targeted immune cell agonist® Heather Cohen, Director, Translational Sciences, Bicycle Therapeutics	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Role of Biomarkers in Personalized Medicine
Precision Oncology Centric Development of Antibody Drug Conjugates Rakesh Dixit, CEO, Bionavigen	14:15 - 14:45
T-cell engagers in immuno-oncology: challenges and advances in biomarker-driven clinical approaches Majid Ghoddusi , Senior Director, Clinical Biomarkers, Poseida Therapeutics	14:45 - 15:15
Design of a comprehensive liquid biopsy assay to monitor real-time anti-tumor response in patients receiving an individualized neoantigen cancer vaccine Desiree Schenk, Principal Scientist, Gritstone Oncology	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Panel Discussion:	16:30 - 17:00
Innovation strategy for the most disruptive, turbulent, and transformative period in modern history. Thriving in the rapidly evolving field of precision medicine George Pell, CEO and Founder, Thirty-Six	17:00 - 17:30
Closing Remarks from the Chairperson Manish Kohli, Professor, Huntsman Cancer Institute, University of Utah	17:30 - 17:55
Drinks Reception & Networking	17:35 - 17:35
End of Day 1	17:35 - 17:35

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairman George Pell, CEO and Founder, Thirty-Six	08:55 - 09:00
State investment in precision medicine research that addresses health disparities Shannon Muir, Co-director of the California Initiative to Advance Precision Medicine in the California Governor’s Office of Planning and Research,	09:00 - 09:30
From Biomarkers to CDx: Strategies to accelerate CDx development and Commercialization
KRAS: From Undruggable Target to CDx and Beyond Mason Israel, Regional Medical Affairs Director, Mirati Therapeutics	09:30 - 10:00
Antibody-based therapeutic and diagnostic development targeting the biological driver of tumorigenesis Progranulin. Ginette Serrero, Chief Executive Officer, Precision Antibody, USA	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Future of RNA Diagnostics in Cancer Michael Milburn, President, CEO, GeneCentric Therapeutics	11:15 - 11:45
Clinical Applications of Biomarkers in Immunotherapy and Oncology
A novel molecular signature to detect, monitor and predict urothelial carcinomas Hideki Furuya, Assistant Professor, Cedars-Sinai Medical Center	11:45 - 12:15
Translational Pathology Biomarker Research in Targeted Protein Degradation Hematologic & Solid Tumor Programs Maria Wang, Associate Director, Bristol-Myers Squibb	12:15 - 12:45
Overcoming Resistance to CAR T Cell Therapies John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences	12:45 - 13:15
Closing Remarks from the Chairperson George Pell, CEO and Founder, Thirty-Six	13:15 - 13:20
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:20 - 14:20
End of Conference	14:20 - 14:20